0001140361-23-056503.txt : 20231206 0001140361-23-056503.hdr.sgml : 20231206 20231206160115 ACCESSION NUMBER: 0001140361-23-056503 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231206 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231206 DATE AS OF CHANGE: 20231206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562020050 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 231469572 BUSINESS ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (619) 949-3681 MAIL ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC. DATE OF NAME CHANGE: 20150820 FORMER COMPANY: FORMER CONFORMED NAME: TARGACEPT INC DATE OF NAME CHANGE: 20000919 8-K 1 ef20016120_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 6, 2023

Gyre Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
000-51173
56-2020050
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

12770 High Bluff Drive
Suite 150
San Diego, CA
  
92130
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (619) 949-3681
N/A
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock
  
GYRE
  
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.
Regulation FD Disclosure.

On December 6, 2023, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“GNI Japan”), which holds an indirect controlling interest of Gyre Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that GNI Japan has amended its consolidated earnings forecast for the full-year 2023 that was previously disclosed on November 6, 2023.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.

Forward Looking Statements

This report and the press release attached as an exhibit contain forward-looking statements that pertain to future operating performance and that are not historic facts. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Japan and/or the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are being furnished herewith:

Exhibit Number
  
Exhibit Title or Description
     
 
Press Release, dated December 6, 2023
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
GYRE THERAPEUTICS, INC.
   
Date: December 6, 2023
By:
/s/ Charles C. Wu, Ph.D.
 
Name:
Charles C. Wu, Ph.D.
 
Title:
Chief Executive Officer


EX-99.1 2 ef20016120_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Dec 6, 2023

 
Company Name:
GNI Group Ltd.
 
Representative:
Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
   
(Security Code: 2160, TSE Growth)
 
Contact Person:
Chief Financial Officer
Toshiya Kitagawa
   
(TEL. 03-6214-3600)

GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts

GNI Group Ltd., (TSE Growth security code: 2160, “the Company” or “the Group” or “we” including all the associated companies) today announced that the Group has updated the consolidated earnings forecast for the full-year 2023, which was published on November 6, 2023, as follows.

1)
Update of Other Income

In the transaction with Gyre Therapeutics, Inc. (“Gyre” and formerly named Catalyst Biosciences, Inc. or “CBIO”) previously disclosed on December 27, 2022, we transferred to CBIO the F351 rights held by the Group outside China. As consideration for the transfer, we received CBIO common and preferred stock. As a result of discussions, only the portion received in common stock has been recorded in other income.

Subsequently, as disclosed on October 31, 2023, all remaining transactions were successfully completed. On November 22, 2023, GNI USA irrevocably elected to convert 13,151 shares of Gyre Series X Convertible Preferred Stock, par value $0.001 per share, (“Convertible Preferred Stock”), which was obtained as consideration for the Group’s ex-China F351 rights, into 8,767,333 shares of Gyre common stock. Subject to the Gyre Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, as amended, it is anticipated that 8,767,333 shares of Gyre common stock will be issued to GNI USA upon such conversion on January 22, 2024.  Accordingly, the Group has recognized a total of approximately ¥8,873 million in other income for the shares of common stock after the conversion at US$0.51 per share of common stock (US$7.65 per share after the 15:1 reverse stock split), which was the closing price of CBIO common stock on the Nasdaq Capital Market on October 30, 2023.

2)
Update of Forecast


1.
The differences between the previous and the updated 2023 consolidated earnings forecast for full-year 2023 (January 1, 2023 – December 31, 2023)



 
Revenue
 
Operating
profit
 
Profit before
tax
 
Profit for
the year
 
Profit
attributable to
owners of the
parent
 
Basic earnings
per share
 
(JPY Million)
 
(JPY Million)
 
(JPY Million)
 
(JPY Million)
 
(JPY Million)
 
(JPY)
 
Previous Forecast (A)
 
26,267
 
7,280
 
6,430
 
4,351
 
2,005
 
42.20
 
Revised Forecast (B)
 
26,300
 
15,744
 
14,865
 
11,234
 
8,971
 
180.42
 
Difference (B-A)
 
33
 
8,464
 
8,435
 
6,883
 
6,966
 
-
 
Difference in ratio (%)
 
0.1%
 
116.3%
 
131.2%
 
158.2%
 
347.4%
 
-
 
(Reference) 2022 Actual
 
17,418
 
1,377
 
767
 
(868)
 
388
 
8.19


2.
Reasons for the differences

Due to the above update to Other Income, the Group recognizes ¥8,464 million in operating profit after deducting such expenses as legal fees. As a result of these factors, the profit items are expected to significantly exceed the full-year forecast announced on November 6, 2023, and we have now revised our full-year consolidated forecast. Please note that this revised forecast does not reflect the latest Gyre common stock valuation that is marked to market, which is under further discussions.


This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (“the Company”). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.

 EX-101.SCH 3 gyre-20231206.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 gyre-20231206_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 gyre-20231206_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image01.jpg begin 644 image01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Dec. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 06, 2023
Entity File Number 000-51173
Entity Registrant Name Gyre Therapeutics, Inc.
Entity Central Index Key 0001124105
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 56-2020050
Entity Address, Address Line One 12770 High Bluff Drive
Entity Address, Address Line Two Suite 150
Entity Address, City or Town San Diego,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 619
Local Phone Number 949-3681
Title of 12(b) Security Common Stock
Trading Symbol GYRE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 8 ef20016120_8k_htm.xml IDEA: XBRL DOCUMENT 0001124105 2023-12-06 2023-12-06 false 0001124105 NASDAQ 8-K 2023-12-06 Gyre Therapeutics, Inc. DE 000-51173 56-2020050 12770 High Bluff Drive Suite 150 San Diego, CA 92130 619 949-3681 false false false false Common Stock GYRE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20016120_8k.htm gyre-20231206.xsd gyre-20231206_lab.xml gyre-20231206_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20016120_8k.htm": { "nsprefix": "gyre", "nsuri": "http://ir.catalystbiosciences.com/20231206", "dts": { "inline": { "local": [ "ef20016120_8k.htm" ] }, "schema": { "local": [ "gyre-20231206.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] }, "labelLink": { "local": [ "gyre-20231206_lab.xml" ] }, "presentationLink": { "local": [ "gyre-20231206_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2022": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231206to20231206", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20016120_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231206to20231206", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20016120_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCountry", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001140361-23-056503-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-056503-xbrl.zip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